By transforming human scar cells into blood vessel cells, scientists at Houston Methodist may have discovered a new way to repair damaged tissue.
The method, described in an upcoming issue of Circulation (early online), appeared to improve blood flow, oxygenation, and nutrition to areas in need.
Cardiovascular scientists at Houston Methodist, with colleagues at Stanford University and Cincinnati Children’s Hospital, learned that fibroblasts — cells that causes scarring and are plentiful throughout the human body — can be coaxed into becoming endothelium, an entirely different type of adult cell that forms the lining of blood vessels.
“To our knowledge, this is the first time that trans-differentiation to a therapeutic cell type has been accomplished with a small molecules and proteins,” said Houston Methodist Research Institute Department of Cardiovascular Sciences Chair John Cooke, M.D., Ph.D., the study’s principal investigator. “In this particular case, we’ve found a way to turn fibroblasts into ‘shapeshifters’ nearly on command.”
Cooke said the regenerative medicine approach provides proof-of-concept for a small molecule therapy that could one day be used to improve the healing of cardiovascular damage or other injuries.
Other research groups have managed to generate endothelial cells cells using infectious virus particles specially engineered to deliver gene-manipulating DNA to cells. The DNA encodes proteins called transcription factors to alter gene expression patterns in such a way that cells behave more like endothelial cells.
“There are problems with using viruses to transfer genes into cells,” Cooke said. “This gene therapy approach is more complicated, and using viral vectors means the possibility of causing damage to the patient’s chromosomes. We believe a small-molecule approach to transforming the cells will be far more feasible and safer for clinical therapies.”
The Latest on: Reprogrammed cells
via Google News
The Latest on: Reprogrammed cells
- Takara Bio Europe AB Announces Licensing Agreement To Enable Cell-Based Therapy Development for Diabeteson May 7, 2021 at 7:42 am
Takara Bio Europe AB (TBEAB) and PanCryos have announced that they have reached a licensing agreement surrounding TBEAB’s clinical-grade human embryonic stem cell lines.
- Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant canceron May 6, 2021 at 3:02 pm
Nanoparticle albumin bound paclitaxel (nab-PTX) is widely used in the clinic to treat different cancers, but the effect of albumin on the distribution of the drug in tumours is not clear. Here the ...
- DSM teams up with Debut Biotech on next generation ‘cell-free’ biomanufacturingon May 6, 2021 at 1:11 pm
Ingredients giant DSM has teamed up with San Diego-based startup Debut Biotech to explore the potential of its ‘cell-free’ biomanufacturing platform, a next-generation manufacturing process it claims ...
- A cancer vaccine built from stem cells? Stanford candidate shows promise in pancreatic tumorson May 6, 2021 at 8:00 am
A team at Stanford University showed that a cancer vaccine made from induced pluripotent stem cells, together with an immune adjuvant, could protect against pancreatic cancer in mouse models. It ...
- Stem cell-based vaccine offers a new approach that may protect against pancreatic canceron May 6, 2021 at 8:00 am
New research by Joseph Wu, Edgar Engelman, and colleagues at Stanford University, U.S., has advanced an old concept to develop a new strategy to train the immune system of mice to recognize cancer ...
- Hydrogel reprogrammes tumour cells back into cancer stem cellson May 5, 2021 at 1:50 am
A hydrogel that rapidly turns cancer cells back into cancer stem cells could help researchers develop personalized therapies ...
- Cell therapy transformation firm Mogrify’s Series A reaches £24mon May 5, 2021 at 12:25 am
B iopharmaceutical company Mogrify has taken its Series A financing to £24 million after raising £12m before the second close of the round. The Cambridge firm is aiming to trans ...
- Mogrify Completes Series A Financing Totaling $33 Million USDon May 4, 2021 at 1:28 am
Mogrify Limited (Mogrify ® ), a biopharmaceutical company aiming to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies, announced today the ...
- The histone reader PHF7 cooperates with the SWI/SNF complex at cardiac super enhancers to promote direct reprogrammingon May 3, 2021 at 12:46 pm
Garry et al. report that the histone reader PHF7 cooperates with the SWI/SNF complex at cardiac super enhancers to increase accessibility to core cardiac transcription factors, thus facilitating ...
- Scientists identify small-molecule cocktail to improve stem cell use in research and disease treatmentson May 3, 2021 at 8:01 am
The unique combination of compounds and drugs greatly improved stem cell survival and reduced cell culture stress.
via Bing News